New Feedonomics for Advertising and Feedonomics Listing & Orders apps deliver enhanced data automation and governance for Shopify merchantsAUSTIN, Texas, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Commerce (Nasdaq: CMRC), an open, intelligent ecosystem of technology solutions and the parent company of AI-enriched product feed management solution Feedonomics, today announced the launch of new capabilities for Shopify merchants to help maximize reach, enhance data, simplify operations and scale. To expand and formaliz ...

Company Signed a Non-Binding Term Sheet for a security exchange between the parties Tel Aviv, Israel, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Viewbix Inc. (Nasdaq: VBIX) (“Viewbix” or the “Company”), a global developer of ad-tech innovative technologies, today announced the signing of a non-binding term sheet outlining the proposed terms for the acquisition of Quantum X Labs Ltd. (“Quantum X Labs” and the “Acquisition”). Under the terms of the term sheet, upon the closing of the Acquisition, Viewbix will acquire ...

核心观点 - Stack Capital Group Inc 公布截至2025年9月30日的第三季度财务业绩，公司账面总值达1.887亿加元，每股账面价值为14.26加元 [1][4][5] - 公司在季度内完成了对OpenAI、Databricks和PsiQuantum等领先科技公司的新投资，并对其投资组合中的多家公司（如SpaceX、Canva、CoreWeave）进行了重点总结 [3][4][9] 财务摘要 - 截至2025年9月30日，公司每股账面价值为14.26加元，较2025年6月30日的14.34加元略有下降 [4] - 公司总账面价值为1.887亿加元 [4][5] - 公司在季度内通过私募成功筹集3500万加元，进一步增强了资本实力 [4] 投资组合公司亮点 - **新投资**：在第三季度，公司完成了对三家定义类别的科技公司的投资：向生成式AI全球领导者OpenAI投资800万美元；向统一数据分析平台Databricks投资210万美元；向量子计算公司PsiQuantum投资50万美元 [3][9] - **SpaceX**：估值从3500亿美元增至4000亿美元，成功完成第11次星舰测试飞行，是航空航天创新和卫星通信（通过星链业务）的全球领导者 [4] - **Canva**：估值从320亿美元增至420亿美元，推出了创意操作系统，并与eXp Realty合作帮助代理商将设计时间减少64% [4] - **Hopper**：推出了由AI驱动的旅行助手HTS Assist，使旅行公司的响应速度提高4倍，服务成本降低65% [4] - **Shield AI**：推出了全球首款AI驾驶的VTOL战斗机X-Bat，并与Huntington Ingalls Industries合作将其自主系统Hivemind集成到海事系统中 [4] - **CoreWeave**：与Meta签署了142亿美元的基础设施协议，并与OpenAI的协议扩大了65亿美元，公司在该季度机会性地减持了部分头寸以锁定收益 [4] 管理层评论 - 公司首席执行官Jeff Parks表示，当前IPO环境强劲，私募市场势头良好，尤其是在AI、国防和机器人等颠覆性领域，公司持续专注于识别和支持有潜力创造长期价值的类别领导者 [5] 每股账面价值构成 - 截至2025年9月30日，公司每股账面价值为14.26加元，其主要构成如下：CoreWeave贡献2.37加元，SpaceX贡献2.28加元，Canva贡献1.30加元，Locus Robotics贡献1.14加元，现金持有为2.35加元 [5]

FDA open to pooling data from ongoing Phase I/II studies of LX2006 with data from pivotal trial, and to earlier co-primary endpoint assessment, to support a Biologics License Application FDA approved comparability report between LX2006 HEK and Sf9 manufacturing processes in November 2025, endorsing use of Sf9 final commercial manufacturing process to begin dosing patients in upcoming pivotal study LX2006 interim clinical data show clinically meaningful improvements across cardiac and neurologic measures o ...

HOUSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appointment of Kathryn Penkus Corzo, R.Ph., MBA to the Company’s Board of Directors, effective November 1, 2025. Ms. Penkus Corzo has vast experience as a biopharma executive, drug developer and independent board director ...

HERZLIYA, Israel, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Nayax Ltd. (Nasdaq: NYAX; TASE: NYAX), a global commerce enablement, payments, and loyalty platform helping merchants scale their business, today announced that it is hosting Nayax Connect LATAM with its partner Integral Vending today for its customers in the region. The event will be hosted at the Live Aqua in Mexico City. In the conference, Nayax will announce its expansion plans for the region and that, as part of the expansion efforts, Nayax has signed ...

WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that management is scheduled to present at the following investor conferences in November: Guggenheim 2nd Annual Healthcare Innovation Conference, fireside chat on Tuesday, November 11, 2025, at 8:00 a.m. ET in Boston.Stifel 2025 Healthcare Conference, fireside chat on We ...

ATHENS, Greece and NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Heidmar Maritime Holdings Corp. (the "Company" or "Heidmar") (NASDAQ: HMR) continues to strengthen its market position by adding super-eco vessels to its managed fleet under commercial and technical management agreements. One Super Eco LR2 newbuilding: A state-of-the-art, super eco LR2 tanker, built at a leading Chinese shipyard, is scheduled to join Heidmar’s fleet under full technical and commercial management in December 2025. This is the sis ...

核心观点 - 公司报告了2025年第三季度稳健的财务业绩，并完成了对EPIC Crude Holdings, LP的100%股权收购，旨在通过业务精简和战略收购成为领先的原油中游提供商 [1][3][6] - 公司预计剥离加拿大NGL业务将带来长期利好，并维持其资本分配框架和单位持有人回报承诺，当前约9.5%的分配收益率具有吸引力 [3][4] 财务业绩摘要 - 第三季度归属于PAA的净利润为4.41亿美元，较去年同期的2.20亿美元增长100% [6][7] - 第三季度运营活动提供的净现金为8.17亿美元，同比增长18% [6][7] - 第三季度归属于PAA的调整后EBITDA为6.69亿美元，同比增长2% [6][7] - 第三季度杠杆率为3.3倍，处于目标范围3.25倍至3.75倍的低端 [6] - 预计2025年全年归属于Plains的调整后EBITDA在28.4亿美元至28.9亿美元之间，其中EPIC收购贡献约4000万美元 [6] 业务分部表现 - 第三季度原油业务调整后EBITDA为5.93亿美元，同比增长3%，增长主要来自近期收购贡献、管道运输量增加和关税上调，部分被某些Permian长输管道合同费率重置和商品价格下跌所抵消 [12][14] - 第三季度NGL业务调整后EBITDA为7000万美元，同比下降4%，主要原因是销售量下降 [12][15] 战略举措与资本活动 - 公司于2025年6月17日签署协议，出售其在加拿大的绝大部分NGL业务予Keyera Corp，交易预计于2026年第一季度完成，完成后公司将保留在美国的绝大部分NGL资产和在加拿大的所有原油资产 [4] - 公司于2025年9月成功发行12.5亿美元高级无抵押票据，用于赎回2025年10月到期的优先票据并为近期宣布的收购提供部分资金 [6] - 公司于2025年10月31日完成从Diamondback Energy和Kinetik Holdings子公司收购EPIC 55%股权的交易，并于2025年11月1日完成从Ares Private Equity基金投资组合公司收购剩余45%股权的交易，总收购价约13.3亿美元（含约5亿美元债务），并同意可能支付高达1.57亿美元的额外款项，与管道系统特定扩建项目挂钩，交易使PAA持有EPIC 100%股权 [6] - 收购EPIC剩余股权有望加速全系统协同效应，包括显著的2026年成本节约，预计回报率为中等两位数，2026年EBITDA倍数约为10倍，未来几年将显著改善，系统将更名为Cactus III [6] 运营与财务数据 - 第三季度每普通股宣布分配额为0.3800美元，同比增长20% [7] - 第三季度原油管道运输量为988.3万桶/天，高于去年同期的916.6万桶/天 [98] - 截至2025年9月30日，现金及现金等价物为11.80亿美元，总债务为94.52亿美元 [29][31]

Based on a continuing trend of decreased mortality in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC), the analyses of overall survival (OS) and progression-free survival (PFS) are expected in late Q1 2026.A new response in a third indication has been observed in the fifth and final dosing cohort of the Phase 1 dose-escalation study of CTX-8371 (PD-1 x PD-L1 bispecific antibody); no dose-limiting toxicities have ...